Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

Daniel Morgensztern, Meghan J. Campo, Suzanne E. Dahlberg, Robert C. Doebele, Edward Garon, David E. Gerber, Sarah B. Goldberg, Peter S. Hammerman, Rebecca S. Heist, Thomas Hensing, Leora Horn, Suresh S. Ramalingam, Charles M. Rudin, Ravi Salgia, Lecia V. Sequist, Alice T. Shaw, George R. Simon, Neeta Somaiah, David R. Spigel, John WrangleDavid Johnson, Roy S. Herbst, Paul Bunn, Ramaswamy Govindan

Research output: Contribution to journalArticlepeer-review

116 Scopus citations


There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.

Original languageEnglish (US)
Pages (from-to)S1-S63
JournalJournal of Thoracic Oncology
Issue number1
StatePublished - Jan 13 2015


  • Immunotherapy
  • Non-small-cell lung cancer
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Molecularly targeted therapies in non-small-cell lung cancer annual update 2014'. Together they form a unique fingerprint.

Cite this